Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of CD5024 0.3% Cream in Atopic Dermatitis
NCT03250624Phase 2Completed
- Sponsor
- Galderma
- Start
- Nov 2016
- Primary completion
- Jun 2017
- Modality
- Placebo
- Countries
- 1
01
Overview
A Phase 2 trial of CD5024 cream placebo in atopic dermatitis (AD), sponsored by Galderma. Started Nov 2016; status: completed.
02
Drugs
CD5024 cream placebo
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03250624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03250624.